Members who have made outstanding contributions, long term commitment and high-level service to the DMDG shall be eligible for DMDG Fellow status. Fellows belong to a distinguished category of membership who have the privilege of membership without site-based representation.
The Committee of the DMDG is calling for nominations for the status of DMDG Fellow. If you would like to nominate someone for this prestigious award, please do so by
completing this form.
Current Fellows of the DMDG are:
Dr Steve Hood
Steve Hood received a PhD in Molecular Toxicology from the University of Surrey in 1993 and joined Glaxo Group Research as an Industrial Post doc in the Molecular Biology department in Greenford where he cloned and expressed CYPs in recombinant cell lines. Steve transferred to GlaxoWellcome at Ware in 1995 and became a manager in the new GSK DMPK Molecular Mechanism and Extrapolation Technology team in 2001. In 2010 Steve seconded to Scinovo and co-ordinated the GSK Oligo delivery (GOLD) project and was also Industrial co-lead of the IMI COMPACT consortium that ran from 2012-17 and evaluated delivery mechanisms for oligos and peptides. After a brief return to DMPK in 2015, Steve joined Bioimaging as a senior Scientific Director, responsible for the external imaging collaborations that are members of the Bioimaging Expertise Network (BEN). As part of this network, Steve was also Co-Director of the GSK Centre for Molecular Imaging (COMI) at the University of Illinois at Urbana Champaign, where he worked closely with Professor Stephen Boppart and his team. In addition to his “day job”, Steve has spent most of the last 2 decades working on GSK’s diverse oligo portfolio and has supported projects ranging from inhaled SiRNAs, TLR antagonists, DMD exon skippers (Drisapersen) and ASOs for TTR (Innotersen) and HBV with Ionis (Bepirovirsen). More recently Steve has been involved with the Wave collaboration (Wve-006), the Jade HBV siRNA in licence project and the formation of the Boston Oligo hub. In Jan 2024 Steve rejoined DMPK in and assumed the role of Director of Oligo ADME Strategy. Steve will continue to develop the DMPK road map and train and mentor the next generation of DMPK Oligo Project Team Members and SMEs.
Dr Suzanne Iverson Hemberg
An organic chemist and molecular/immunotoxicologist by training (Queen’s University and University of Toronto); a biotransformation scientist and ADME manager by practice. Born, raised and educated in Canada, I moved to Sweden in 2002 to undertake a postdoctoral position with Dr. Sten Orrenius at Karolinska Institutet. I joined AstraZeneca in Södertälje, Sweden in late 2003 with the then Biotransformation Section. In 2006 I started my journey in management of the local ADME group in a global organization which, after 2008, included the autoradiography group. This “merger” of sorts led to my driving the mass spectrometry imaging build in AstraZeneca, which has culminated in an internal capability in this area. In addition, I have been a core member of various global strategy teams set up to lead the Biotransformation and ADME sciences for the global business; and I have been active in both internal and external scientific collaborations which have included the direct supervision of two postdocs. In March 2022, I became the CEO of Toxicology Knowledge Team AB (TKT) in Sweden. In addition to my work with the DMDG, I am an active member of the PK-Metabolism sub-committee of the Swedish Pharmaceutical Society.
Dr Barry Jones
Dr Barry Jones is Chief Scientist Global DMPK at Pharmaron UK. This role enables Barry to play a leading role in continued development of Pharmaron's global DMPK services with its unique breadth from discovery through to registration. Barry previously worked for AstraZeneca where he held a variety of director level roles in DMPK over eight years. Prior to AZ, Barry spent 20 years in DMPK at Pfizer Global Research & Development. Throughout his industrial career he has focused on setting strategic direction, identifying new opportunities for research/development programs and adding significant insight/expertise and value to drug discovery and development projects with a focus in the area of in vitro DMPK science and drug-drug interactions.
Prof Dennis Smith
Dennis Smith started his career at Fisons Pharmaceuticals and his experience over 12 years there concerned inhalation, oral and intravenous compounds For 20 years he was at Pfizer Global Research and Development, Sandwich where he was Vice President-Pharmacokinetics, Dynamics and Metabolism. He has helped in the Discovery and Development of eight marketed NCEs. He now works on a part-time basis in an advisory and academic role. Academic appointments include Visiting Professor at the University of Liverpool and Honary Professor at the University of Capetown. His research interests and publications (over 150) span all aspects of Drug Discovery and Development particularly where drug metabolism knowledge can impact on the design of more efficacious and safer drugs. Recent articles provide a balanced view of the discovery, development and use of medicines (e.g Communicating the risks and benefits of medicines, Will biomedical innovation change the future of healthcare? Others have commented on the role of metabolites in drug safety, the misunderstandings around protein binding, new ways of evaluating toxicokinetics, why metabolites circulate and the use of AMS technology. He has co-authored three books... "An Introduction to Pharmacokinetics" was widely adopted as a reference book for many university courses, “Pharmacokinetics and Metabolism in Drug Design” has become almost a “best selling” title in Medicinal Chemistry, a third edition has recently been published. The latest book is “Reactive Metabolites”. He has in addition edited and a contributing author in “Metabolism, Pharmacokinetics and Toxicity of Functional Groups-Impact of chemical building blocks on ADMET” (RSC Drug Discovery) and the 3rd edition of the “Encyclopedia of Drug Metabolism and Interactions Vol 3”. He is a member of the editorial board of Xenobiotica, Drug Metabolism Reviews, Bioanalysis etc.
Prof Ian Wilson
Ian Wilson trained as a biochemist at the University of Manchester Institute of Science and Technology UMIST followed by a PhD in the Chemistry Dept. at Keele Univ. on the GC of insect moulting hormones. After a Postdoc using HPLC for penicillamine analysis at UCL he joined Pharma where he had a career in drug metabolism and bioanalysis spanning over 30 years (Hoechst, ICI, Zeneca and AstraZeneca). On leaving AZ he joined Imperial College (London) in 2012 where he is now a Visiting Prof of Drug Metabolism and Molecular Toxicology (he is also a visiting Prof at Liverpool Univ.). He uses advanced analytical methods, especially those based on UHPLC and ion mobility separations, to try to characterize and understand biological systems. Currently these are focussed on high resolution, high throughput methods that applied to problems in metabolic phenotyping (metabonomics/metabolomics), DMPK/Tox, systems biology and the microbiome. and is the author, or co-author, of over 600 papers, reviews or book chapters. He is, much to his own surprise, a fellow of the DMDG, and has received awards in separation and analytical science from the RSC and the Chrom. Soc.
